TAG
Immunotherapy
Personalized mRNA Cancer Vaccine Cuts Melanoma Recurrence Risk by 42% in Landmark Phase 3 Trial
An experimental personalized cancer vaccine cut the risk of skin cancer recurrence or death by 42 percent. Pharmaceutical leaders Moderna and Merck presented the...


